Domestic News: New Products, Technological Innovations, and Regulatory Trends
1. Toho University Becomes First in Japan to Obtain Expanded Approval for Medical Devices Using Only Domestic Registry Data
News Highlights
Professor Masato Nakamura of Toho University School of Medicine, in collaboration with the Japanese Association of Cardiovascular Intervention and Therapeutics (JACIT), utilized solely the results of a domestic registry (ALLIANCE registry) to obtain a partial change approval for the expanded indication of drug-coated balloons (DCB).
Impact on the Industry
This marks the first instance in Japan where pharmaceutical approval for a medical device was obtained based solely on the evaluation of domestic registry results. It is expected that the pharmaceutical approval review process for medical devices utilizing real-world data (RWD) will further accelerate, enabling more rapid product introduction.
2. Two Regenerative Medicine Products Using iPS Cells to Undergo Price Review for Insurance Coverage by the Central Social Insurance Medical Council
News Highlights
At the General Meeting of the Central Social Insurance Medical Council (Chuikyo) held on April 8, 2026, the handling of two regenerative medicine products using iPS cells within the framework of public medical insurance was approved. A candidate drug for Parkinson's disease will be considered as a "pharmaceutical product," and a myocardial cell sheet for severe heart failure will be considered as a "medical material." Price reviews for these products will proceed.
Impact on the Industry
This is a significant step towards the practical application of the world's first regenerative medicine products using iPS cells. With insurance coverage expected as early as this summer, this development will have a profound impact on the entire medical industry, strengthening Japan's international competitiveness in the field of regenerative medicine and offering new treatment options for intractable diseases.
3. Riverfield Selected for "NVIDIA Inception Program" for AI Development for Surgical Support Robots
News Highlights
Riverfield Inc., a developer of surgical support robots, announced that it has been selected for the "NVIDIA Inception Program," an AI startup support program provided by NVIDIA, the world's largest AI semiconductor company.
Impact on the Industry
Riverfield is focusing on developing intraoperative navigation technology that visualizes force feedback information (such as gripping force and traction force). Through collaboration with NVIDIA's GPU technology and global ecosystem, the implementation of advanced image analysis and AI inference will be accelerated, and Riverfield is expected to gain an advantage in the development competition for next-generation surgical support robots that improve surgical safety and reproducibility.
International News: Regulatory Trends, New Technologies, Market Environment
1. Israeli Company Innoventric Receives FDA Breakthrough Designation for Tricuspid Regurgitation Treatment Device
News Highlights
Innoventric, an Israeli medical device company, announced that its "Unica System," intended for the treatment of severe tricuspid regurgitation (TR), has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
Impact on the Industry
This designation will allow for prioritized review and interactive feedback from the FDA, paving the way for early introduction to the U.S. market. It is attracting attention as an innovative device that provides a safe and effective new treatment option for high-risk patients for whom existing catheter treatments are difficult.
2. Surgical Support Robot Market: Competitors to Intuitive Surgical Emerge in Soft Tissue Applications
News Points
The soft tissue robotic surgery market has long been dominated by Intuitive Surgical (da Vinci system). However, in recent years, emerging companies developing more affordable and accessible systems have begun to appear.
Impact on the Industry
It is anticipated that new, cost-competitive surgical support robots will be introduced, targeting rapidly expanding Ambulatory Surgical Centers (ASCs) in the United States. As the market's oligopoly breaks down, hospitals will have more choices, potentially promoting further adoption and lower costs for robotic surgery.
3. Impact of U.S. Tariff Policy on MedTech Companies and Their Responses
News Points
In response to the new tariff policies by the Trump administration, U.S. MedTech companies are implementing initiatives to absorb the impact through overall organizational cost reduction and supply chain optimization, while avoiding price pass-throughs or cuts in research and development (R&D) expenditures.
Impact on the Industry
Some major companies have estimated the impact of tariffs on revenue to range from $200 million to $500 million annually. However, the industry as a whole maintains resilience, and a clear stance is emerging to sustain long-term growth foundations through strategic responses such as logistics optimization and securing alternative suppliers.
Summary: Key Industry Trends
From today's news, it can be seen that the medical device industry is currently moving along the following three major trends:
- Utilization of Real-World Data (RWD) and Acceleration of Approval Processes (e.g., Toho University's registry utilization case, FDA's Breakthrough Device Designation)
- Acceleration of the Integration of AI/Robotics and Medicine (e.g., Riverfield's collaboration with NVIDIA, intensified competition in the soft tissue robotics market)
- Practical Application and Social Implementation of Regenerative Medicine (e.g., movements towards insurance coverage for iPS cell products)
In particular, the movements towards insurance coverage for iPS cell products originating from Japan and the establishment of new approval approaches utilizing RWD have the potential to be historical turning points in the development of Japan's medical device and regenerative medicine fields.
Reference Links
- Toho University: First in Japan to obtain approval for expanded indications of medical devices using only domestic registries for evaluation
- Ministry of Health, Labour and Welfare: Central Social Insurance Medical Council General Meeting
- Nikkei: Two iPS cell products, drug and material, price consideration approved by Chuikyo
- Yakuji Nippo: Riverfield selected for "NVIDIA Inception Program"
- Cardiac Interventions Today: Innoventric's Unica System Granted FDA Breakthrough Device Designation
- Modern Healthcare: Intuitive Surgical's rivals eye soft tissue robotic surgery
- MedTech Dive: How medtech companies are coping with tariff challenges
Need help with Japan's medical device approval?
Our regulatory affairs consultants specializing in digestive endoscopy devices provide end-to-end support from strategy to document preparation. Contact us for a free initial consultation.
Free Consultation